Sensus Healthcare, Inc. (NASDAQ:SRTS) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 8.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 146,404 shares of the company’s stock after buying an additional 11,525 shares during the period. Geode Capital Management LLC owned about 0.89% of Sensus Healthcare worth $849,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its position in Sensus Healthcare by 128.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Sensus Healthcare by 34.4% during the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after buying an additional 100,294 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Sensus Healthcare during the second quarter worth approximately $156,000. Marshall Wace LLP grew its holdings in Sensus Healthcare by 152.4% in the 2nd quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after buying an additional 46,732 shares in the last quarter. Finally, XTX Topco Ltd increased its position in Sensus Healthcare by 76.0% in the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after acquiring an additional 13,619 shares during the period. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Stock Down 4.2 %

NASDAQ:SRTS opened at $6.54 on Friday. The stock has a fifty day simple moving average of $7.68 and a 200 day simple moving average of $6.67. The firm has a market capitalization of $107.18 million, a price-to-earnings ratio of 11.47 and a beta of 1.21. Sensus Healthcare, Inc. has a 1-year low of $2.61 and a 1-year high of $9.33.

Wall Street Analysts Forecast Growth

SRTS has been the subject of a number of analyst reports. HC Wainwright boosted their price target on Sensus Healthcare from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Maxim Group upped their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.